Monday, 7 October 2024
  
Login

Australia's most trusted
source of pharma news

Monday, 07 October 2024
News

Pfizer pulls $480M drug worldwide

Posted 27 September 2024 AM

Pfizer has announced it is voluntarily withdrawing its sickle cell disease (SCD) treatment Oxbryta from all markets.

The move is based on "the totality of clinical data", which suggest an "imbalance in vaso-occlusive crises and fatal events", according to the pharma. This indicates that the overall benefit of Oxbryta can no longer be considered to outweigh the risk in the approved sickle cell patient population.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (6)

Sales & Customer Relations (15)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (6)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.